Truist raised the firm’s price target on RadNet (RDNT) to $94 from $80 and keeps a Buy rating on the shares. The firm, which is updating its estimates to reflect Q3 earnings, raised FY24 guidance and the recently announced AI collaboration with GE Healthcare (GEHC), notes that it is raising its FY24, FY25 and FY26 adjusted EBITDA estimates for RadNet to $280.4M, $308.0M and $336.0M, respectively.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDNT:
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solutionGE
- RadNet Achieves Record Revenue and Adjusts 2024 Guidance
- Cigna drops pursuit of Humana: Morning Buzz
- GE HealthCare and RadNet collaborate in imaging systems innovation
- RadNet reports Q3 adjusted EPS 18c, consensus 15c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
